SAN DIEGO, April 15, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing ...

VG801 is the first FDA IND clearance for novel mRNA trans-splicing gene therapy, delivering the full-length functional ABCA4 gene to target the genetic root cause of retinal dystrophies associated ...

Essentially all cells in an organism's body have the same genetic blueprint, or genome, but the set of genes that are ...

Researchers at Harvard Medical School and Brigham and Women's Hospital designed an ingestible capsule that delivers liquid mRNA to the intestines, producing gene expression and reducing ...

A new type of mRNA vaccine is more scalable and adaptable to continuously evolving viruses such as SARS-CoV-2 and H5N1, according to a study by researchers at University of Pittsburgh School of ...

The disruption causes a protein imbalance that can result in mis-splicing of multiple genes involved in brain function, and may explain why some of the social and behavioral outcomes of ASD ...

The mRNA vaccine, known as BTN116, developed by the German biotechnology company BioNTech, is the first of its kind and has entered phase 1 clinical trials in seven countries.

Vaccines using mRNA technology weren’t immune to the latest round of federal research cuts.